Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol

BACKGROUND: The intensive study of predictive factors has strongly ameliorated the therapeutic flow-chart of metastatic colorectal cancer (mCRC) by allowing the selection of patients who benefit from specific therapies. For instance, in mRAS (mutated RAS) mCRC patients, anti-EGFR drugs (cetuximab an...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Ther Adv Med Oncol
Huvudupphovsmän: Ottaiano, Alessandro, Scala, Stefania, Santorsola, Mariachiara, Trotta, Anna Maria, D’Alterio, Crescenzo, Portella, Luigi, Clemente, Ottavia, Nappi, Anna, Zanaletti, Nicoletta, De Stefano, Alfonso, Avallone, Antonio, Granata, Vincenza, Notariello, Carmen, Luce, Amalia, Lombardi, Angela, Picone, Carmine, Petrillo, Antonella, Perri, Francesco, Tatangelo, Fabiana, Di Mauro, Annabella, Albino, Vittorio, Izzo, Francesco, Rega, Daniela, Pace, Ugo, Di Marzo, Massimiliano, Chiodini, Paolo, De Feo, Gianfranco, Del Prete, Paola, Botti, Gerardo, Delrio, Paolo, Caraglia, Michele, Nasti, Guglielmo
Materialtyp: Artigo
Språk:Inglês
Publicerad: SAGE Publications 2021
Ämnen:
Study Protocol
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8010802/
https://ncbi.nlm.nih.gov/pubmed/33854566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835921989223
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk